Workflow
J&J(JNJ)
icon
Search documents
Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million
CNBC· 2024-01-23 18:59
Containers of Johnson and Johnson baby powder are displayed on a Walgreens shelf on April 05, 2023 in San Anselmo, California.Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into whether the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which are slated to go t ...
J&J(JNJ) - 2023 Q4 - Earnings Call Presentation
2024-01-23 18:15
Johnson & Johnson Innovative Medicine Pipeline Key Events in 2024* POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA SSSuuummm ooofff PRCrehogegicorkan mC Ch hCaahnnaggneege SSSuuummm ooofff PRCrehogegicorkan mC Ch hCaahnnaggneege SSSuuuPmmmh oaoosfff e PRC rIehIogIegicorkan mC Ch hCaahnnaggneege OPSUMIT (macitentan) US OPSUMIT (macitentan) US SIMPONI (golimumab) TREMFYA (guselkumab) EU Pediatric Pulmonary Arterial Hypertension Pediatric Pulmonary Arterial Hypertension EU Pediatric ...
J&J(JNJ) - 2023 Q4 - Earnings Call Transcript
2024-01-23 18:14
Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Conference Call January 23, 2024 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman & CEO Joseph Wolk - EVP & CFO Conference Call Participants Joanne Wuensch - Citibank Terence Flynn - Morgan Stanley Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Louise Chen - Cantor Fitzgerald Matt Miksic - Barclays Geoff Meacham - Bank of America Danielle Antalffy - UB ...
Why Johnson & Johnson Stock Was Pulling Back Today
The Motley Fool· 2024-01-23 17:41
Shares of Johnson & Johnson (JNJ -1.59%) were sliding today as the diversified healthcare company edged past estimates in its fourth-quarter earnings report, but agreed to pay $700 million to settle lawsuits saying that its talc-based baby powder caused cancer. J&J also announced a settlement with the state of Washington over opioid-related claims for $149.5 million and said it had now resolved all pending litigation over the opioid crisis. As of 11:08 a.m. ET, the stock was down 2%. A good, but not good en ...
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
Zacks Investment Research· 2024-01-23 17:06
Johnson & Johnson’s (JNJ) fourth-quarter 2023 earnings came in at $2.29 per share, which beat the Zacks Consensus Estimate of $2.27. Earnings rose 11.7% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported fourth-quarter earnings of $1.70 per share, up 39.3% from the year-ago quarter.Sales of this drug and medical devices giant came in at $21.4 billion, beating the Zacks Consensus Estimate of $21.1 billion by a slight ma ...
J&J agrees to pay $700M to settle talc probes in 42 states
New York Post· 2024-01-23 16:31
Johnson & Johnson on Tuesday said it had reached a tentative settlement to resolve probes by states into whether it misled consumers about the safety of its talc products, which thousands of lawsuits claim can cause cancer.The deal includes 42 states and Washington, DC. The company tentatively agreed to pay about $700 million to settle the states’ claims, according to the Wall Street Journal.“Consistent with the plan we outlined last year, the company continues to pursue several paths to achieve a comprehe ...
Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research· 2024-01-23 16:00
For the quarter ended December 2023, Johnson & Johnson (JNJ) reported revenue of $21.4 billion, down 9.8% over the same period last year. EPS came in at $2.29, compared to $2.35 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $21.11 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +0.88%, with the consensus EPS estimate being $2.27.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...
Johnson & Johnson undershoots full-year earnings guidance
Proactive Investors· 2024-01-23 13:16
New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today’s annual earnings call, but slightly undershot with its adjusted earnings results. The company reported a reported 6.5% year-on-year growth in sales of $85.2 billion but the full-year earnings per share (EPS) depicted a different trend, decreasing by 15.3% to $5.20 a share. This decline was primarily due to a special one-time charge incurred in the first quarter. On an adjusted basis, EPS increased by 11.1% ...
Johnson & Johnson's stock price is at a critical turning point
MarketBeat· 2024-01-23 13:12
Key PointsJohnson & Johnson has solid growth in core segments and reiterated its guidance for the year. The dividend is safe for 2024 and may include another increase this spring. Analysts have trimmed their targets and may cap gains for this stock in the year's first half. 5 stocks we like better than Johnson & JohnsonJohnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, alt ...
J&J Q4 earnings narrowly top expectations
Invezz· 2024-01-23 12:20
Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.Johnson & Johnson’s guidance for fiscal 2024Copy link to sectionThe pharmaceutical giant now forecasts its full-year sales to fall between $87.8 billion and $88.6 billion on up to $10.75 of per-share earnings. Analysts, in comparison, were at $87.9 billion and $10.68 a share, respectively. Joaquin Duato – the chief executive of Jo ...